BioSpace News Archive

Drug Development

Novartis positive 52-week PREVENT data confirm Cosentyx® efficacy in addressing entire axSpA spectrum

Phase III PREVENT study met 52-week primary endpoint of ASAS40, showing a sustained response in patients with non-radiographic axial spondyloarthritis (nr-axSpA)(1)

October 2, 2019
·
13 min read
Biotech Bay

Outset Medical Receives U.S. Department of Health and Human Services Contract to Provide Tablo Dialysis Systems for Disaster Recovery Response

Proven technology for personalized dialysis treatment aligns with White House national kidney initiative

October 2, 2019
·
3 min read
Job Trends

Patients Are Now Being Treated with a Civica Rx Medication

First deliveries of Vancomycin pave the way for it to be available to all member health systems later this month

October 2, 2019
·
5 min read
Biotech Beach

Axonics® Announces Exclusive Agreement to Supply Sacral Neuromodulation Systems to Leading Urology Practice Group

Axonics Modulation Technologies, Inc. announced that it has entered into an exclusive agreement to supply the Axonics r-SNM® System to Adult Pediatric Urology and Urogynecology, headquartered in Omaha, Nebraska.

October 2, 2019
·
3 min read
Job Trends

The Myeloma Crowd Launches Psoriasis / Multiple Myeloma Study Using Its HealthTree® Platform

HealthTree IRB-Approved Data Study to Identify Potential Correlations Between Diseases

October 2, 2019
·
2 min read
Pharm Country

DolCas Biotech Launches Bergacyn® for Heart and Liver Health

Synergistic, clean-label botanical low-dose formulation also available in organic option

October 2, 2019
·
4 min read
Business

Nabsys Raises $21 Million Equity Round Led by Hitachi High-Technologies

Nabsys, the pioneer in high-definition genome mapping, announced that it has closed on a $21 million equity round led by Hitachi High-Technologies Corporation.

October 2, 2019
·
2 min read
Deals

Immunovant to Merge with Health Sciences Acquisitions Corporation, Creating New Publicly Listed FcRn-Focused Company

Top shareholders of Immunovant post-closing to include Roivant Sciences and blue-chip biotech investors, including RTW Investments, BVF Partners, Adage Capital Management, Cormorant Asset Management, Eventide Asset Management, and Perceptive Advisors

October 2, 2019
·
13 min read
Drug Development

ReNeuron Announces Clinical Update and Conference Presentations

“Clear efficacy signal” in Phase 2a study of hRPC cell therapy in retinitis pigmentosa

October 2, 2019
·
5 min read
Deals

Vision Innovation Partners Acquires Tenth Practice, Continuing Aggressive Mid-Atlantic Growth

Vision Innovation Partners is pleased to announce its acquisition of Metropolitan Ophthalmology Associates, a leading ophthalmology practice with locations in Chevy Chase, Maryland and McLean, Virginia.

October 2, 2019
·
2 min read